GlassScriptPhysician profile
Naushin Shareef
NPI 1336377977
$1,552.58
in general payments reported to CMS, 2019-2025
31 companies · $22.78 in 2025
The $22.78 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,265 · 2020: $212 · 2021: $29.33 · 2024: $23.76 · 2025: $22.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $46.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $46.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $265.41 | 2019 | |
| Astellas Pharma US INC | $122.14 | 2019-2020 | |
| Genentech USA, INC. | $97.10 | 2019 | |
| Pfizer INC. | $89.32 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $82.19 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $77.99 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $76.33 | 2019-2020 | |
| Celgene Corporation | $59.30 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $57.50 | 2019-2021 | |
| Pharmacyclics LLC, An Abbvie Company | $52.41 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $49.66 | 2019 | |
| Incyte Corporation | $46.04 | 2019 | |
| Lilly USA, LLC | $41.87 | 2019 | |
| Verastem, INC. | $39.78 | 2019-2020 | |
| Amgen INC. | $37.10 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $35.88 | 2019 | |
| Janssen Pharmaceuticals, INC | $28.41 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.39 | 2019 | |
| Rigel Pharmaceuticals, INC. | $24.95 | 2019 | |
| Dova Pharmaceuticals | $24.87 | 2019 | |
| Amag Pharmaceuticals, INC. | $24.17 | 2019 | |
| Abbvie INC. | $23.76 | 2024 | |
| Eisai INC. | $23.12 | 2019 | |
| Janssen Scientific Affairs, LLC | $22.78 | 2025 | Tecvayli |
| Alexion Pharmaceuticals, INC. | $19.99 | 2019 | |
| Taiho Oncology, INC. | $19.64 | 2019 | |
| Daiichi Sankyo INC. | $18.86 | 2019 | |
| Genzyme Corporation | $18.07 | 2019 | |
| Seagen INC. | $17.39 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $17.24 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naushin Shareef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.